Medicinova inc (MNOV)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Revenues:
Revenues

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

3

-

83

493

191

-

-

-

-

0

0

Operating expenses:
Research, development and patents

1,250

1,828

1,150

1,465

1,633

214

2,370

1,379

1,661

1,157

1,268

897

900

591

889

962

1,075

913

586

797

719

782

893

835

747

938

785

946

695

778

872

1,483

1,878

1,440

1,679

2,040

2,623

2,177

2,304

Cost of revenues

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

General and administrative

1,673

395

1,494

2,716

3,345

277

4,657

2,020

3,004

2,249

2,523

1,907

2,122

849

1,955

2,242

2,316

1,822

1,007

1,480

1,495

1,600

1,451

1,295

1,615

1,634

1,456

1,842

1,724

1,677

1,573

1,297

2,185

2,061

2,227

1,682

2,352

1,971

1,847

Total operating expenses

2,924

2,224

2,645

4,182

4,979

492

7,027

3,400

4,666

3,407

3,791

2,804

3,023

1,440

2,844

3,204

3,391

2,736

1,594

2,277

2,214

2,382

2,345

2,131

2,363

2,572

2,242

2,788

2,420

2,455

2,446

2,781

4,064

3,502

3,907

3,722

4,976

4,148

4,151

Operating loss

-2,924

-2,224

-2,645

-4,182

-4,979

-492

-7,027

-3,400

-4,666

-3,407

-3,791

-2,804

-3,023

-1,440

-2,844

-3,204

-3,391

-2,736

-1,594

-2,277

-2,214

-2,382

-2,345

-2,131

-2,363

3,427

-2,242

-2,788

-2,417

-2,421

-2,362

-2,288

-3,873

-3,502

-3,907

-3,722

-4,976

-4,148

-4,151

Interest income

223

247

288

307

304

289

268

250

131

63

41

24

15

20

13

18

14

15

10

6

6

3

9

11

12

6

7

5

1

2

4

6

11

12

8

16

25

33

201

Other income (expense)

-12

4

-21

-7

-22

-0

-20

5

-7

-20

-3

-6

4

-64

2

11

3

12

22

14

4

-

2

0

-

18

0

1

4

10

14

0

4

1

-4

31

52

52

43

Debt related credit/(charge)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

Write-off of debt related costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Impairment charge on investment securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-869

64

Foreign exchange gain/(loss)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3

2

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-0

-1

943

652

659

406

Loss before income taxes

-

-

-

-

-

-

-

-

-

-3,355

-3,753

-2,786

-3,012

-1,449

-2,834

-3,198

-3,380

-2,733

-1,606

-2,285

-2,212

-2,389

-2,338

-2,120

-2,350

3,414

-2,234

-2,784

-2,420

-2,428

-2,372

-2,281

-3,867

-3,491

-3,893

-4,681

-5,655

-

-

Income tax (expense)

-

-

-

-

-

-

-

-

-

-1,752

2

2

4

-0

1

1

1

1

1

1

2

-8

1

1

1

1

1

1

-1

-

5

-

-

-

-

0

-

6

0

Net loss applicable to common stockholders

-2,713

-1,984

-2,378

-3,881

-4,697

-207

-6,779

-3,144

-4,543

-1,602

-3,755

-2,788

-3,016

-1,449

-2,835

-3,199

-3,381

-2,735

-1,607

-2,286

-2,215

-

-2,340

-

-

-

-

-

-

-

-2,378

-2,281

-3,867

-3,503

-3,893

-4,681

-5,655

-5,700

-4,334

Accretion to redemption value of redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

Deemed dividend resulting from beneficial conversion feature on Series C redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

Net loss applicable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,121

-2,352

3,413

-2,236

-2,786

-2,419

-2,433

-2,378

-2,281

-3,867

-3,503

-3,893

-4,681

-5,655

-5,700

-4,334

Basic and diluted net loss per common share

-0.06

-0.05

-0.05

-0.09

-0.11

0.00

-0.16

-0.08

-0.12

-0.04

-0.11

-0.08

-0.09

-0.04

-0.08

-0.10

-0.11

-0.09

-0.06

-0.09

-0.09

-0.09

-0.10

-0.09

-0.10

0.19

-0.10

-0.14

-0.14

-0.14

-0.14

-0.14

-0.24

-0.19

-0.25

-0.31

-0.45

-0.46

-0.35

Shares used to compute basic and diluted net loss per common share

43,949

43,755

43,343

43,069

42,467

41,930

41,879

41,557

39,132

36,218

35,156

34,646

34,527

34,537

34,476

32,576

30,356

30,017

26,931

24,827

24,538

24,282

24,149

24,141

23,697

22,497

22,301

20,299

17,691

17,275

16,585

16,143

16,088

16,058

15,327

15,319

12,547

12,453

12,431

Net loss applicable to common stockholders

-2,713

-1,984

-2,378

-3,881

-4,697

-207

-6,779

-3,144

-4,543

-1,602

-3,755

-2,788

-3,016

-1,449

-2,835

-3,199

-3,381

-2,735

-1,607

-2,286

-2,215

-

-2,340

-

-

-

-

-

-

-

-2,378

-2,281

-3,867

-3,503

-3,893

-4,681

-5,655

-5,700

-4,334

Net loss applicable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,121

-2,352

3,413

-2,236

-2,786

-2,419

-2,433

-2,378

-2,281

-3,867

-3,503

-3,893

-4,681

-5,655

-5,700

-4,334

Other comprehensive loss, net of tax:
Foreign currency translation adjustments

-0

-0

-0

3

-1

0

-0

-4

5

-0

0

-0

1

-11

2

5

9

-1

1

-1

-0

-16

-6

0

2

-2

0

-3

-6

-9

2

1

-6

-1

5

2

-7

-

-

Comprehensive loss

-2,713

-1,984

-2,379

-3,878

-4,698

-207

-6,780

-3,148

-4,537

-1,603

-3,754

-2,789

-3,014

-1,460

-2,833

-3,193

-3,371

-2,736

-1,606

-2,288

-2,215

-2,397

-2,347

-2,120

-2,349

3,410

-2,235

-2,789

-2,425

-2,443

-2,375

-2,279

-3,874

-3,504

-3,888

-4,679

-5,663

-

-